MarketCap
Facebook
X
TelegramQuarterly report 2023-Q3
added 11-02-2023
ImmunoGen Operating Expenses 2011-2026 | IMGN
Annual Operating Expenses ImmunoGen
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 330 M | 195 M | 155 M | 38.5 M | 36.7 M | 33.9 M | 36.9 M | 28.2 M | 24.5 M | 21.5 M | 89.6 M | 79.5 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 330 M | 21.5 M | 89.1 M |
Quarterly Operating Expenses ImmunoGen
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 87.5 M | 87.3 M | 92.3 M | - | 92.8 M | 75.2 M | 60.9 M | - | 43.4 M | 44.3 M | 44.6 M | - | 34.9 M | 33.4 M | 37.1 M | 36.4 M | 31.2 M | 56.6 M | 50.2 M | 53.8 M | 56.5 M | 48 M | 56.6 M | 49.3 M | 39.6 M | 44.2 M | 41.4 M | 42.5 M | 46.5 M | 48 M | 46.5 M | 46.3 M | 43.5 M | 46.3 M | 43.5 M | 34.5 M | 35.1 M | 34.5 M | 35.1 M | 26.3 M | 28.6 M | 26.3 M | 28.6 M | 27.1 M | 29.3 M | 27.1 M | 29.3 M | 20.4 M | 22 M | 20.4 M | 22 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 92.8 M | 20.4 M | 43.9 M |
Operating Expenses of other stocks in the Biotechnology industry
| Issuer | Operating Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
432 M | - | 2.43 % | $ 254 M |  Germany |
 |
Advaxis
ADXS
|
22 M | - | -9.65 % | $ 45.9 M |  USA |
 |
Akouos
AKUS
|
86.8 M | - | 0.23 % | $ 488 M | USA |
 |
Allakos
ALLK
|
196 M | - | - | $ 28.6 M | USA |
 |
AlloVir
ALVR
|
46.2 M | - | 4.14 % | $ 49.1 M | USA |
 |
I-Mab
IMAB
|
1.49 B | - | - | $ 866 M |  China |
 |
Aeglea BioTherapeutics
AGLE
|
210 M | - | - | $ 1.01 B | USA |
 |
Ampio Pharmaceuticals
AMPE
|
9.57 M | - | -11.43 % | $ 502 K | USA |
 |
Midatech Pharma plc
MTP
|
4.78 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
2.66 B | - | - | $ 40.3 B | USA |
 |
Applied Molecular Transport
AMTI
|
127 M | - | - | $ 10.1 M | USA |
 |
Applied Therapeutics
APLT
|
74.5 M | - | - | $ 8.42 M | USA |
 |
Aptorum Group Limited
APM
|
20.7 M | $ 0.9 | -0.02 % | $ 6.62 M | China |
 |
Genfit SA
GNFT
|
78.3 M | - | 2.54 % | $ 160 B |  France |
 |
ACADIA Pharmaceuticals
ACAD
|
708 M | $ 22.46 | 0.72 % | $ 3.72 B | USA |
 |
Aptinyx
APTX
|
62.6 M | - | -39.0 % | $ 4.57 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.22 M | - | -1.52 % | $ 24.7 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
29.8 M | - | - | $ 7.46 M |  Israel |
 |
Brainstorm Cell Therapeutics
BCLI
|
31.7 M | - | -2.5 % | $ 5.88 M | USA |
 |
BioDelivery Sciences International
BDSI
|
106 M | - | -4.8 % | $ 255 M | USA |
 |
AIkido Pharma
AIKI
|
179 M | - | 1.93 % | $ 17.4 M | USA |
 |
Cara Therapeutics
CARA
|
26.7 M | - | -3.03 % | $ 260 M | USA |
 |
CASI Pharmaceuticals
CASI
|
38.9 M | - | - | $ 35.4 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
629 M | - | - | - |  Russia |
 |
Fennec Pharmaceuticals
FENC
|
50.9 M | $ 6.81 | -0.58 % | $ 195 M | USA |
 |
ChromaDex Corporation
CDXC
|
66.9 M | - | -0.88 % | $ 598 M | USA |
 |
Aeterna Zentaris
AEZS
|
13.3 M | - | 5.93 % | $ 314 M |  Canada |
 |
Galectin Therapeutics
GALT
|
20.1 M | $ 2.37 | -0.04 % | $ 151 M | USA |
 |
AgeX Therapeutics
AGE
|
24.2 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aravive
ARAV
|
80 M | - | -13.39 % | $ 1.45 M | USA |
 |
Aridis Pharmaceuticals
ARDS
|
23.4 K | - | 17.91 % | $ 11.1 M | USA |
 |
Greenwich LifeSciences
GLSI
|
16 M | $ 23.76 | -0.96 % | $ 309 M | USA |
 |
BioNTech SE
BNTX
|
512 M | $ 101.26 | -0.78 % | $ 27.2 B | Germany |
 |
Checkpoint Therapeutics
CKPT
|
56.2 M | - | - | $ 169 M | USA |
 |
Avenue Therapeutics
ATXI
|
4.49 M | - | -52.27 % | $ 4.45 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
66.5 M | - | - | $ 26.5 M | USA |
 |
Aquestive Therapeutics
AQST
|
85.5 M | $ 4.14 | 1.1 % | $ 443 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
137 M | $ 23.67 | 1.07 % | $ 3.01 B | USA |
 |
Heron Therapeutics
HRTX
|
281 M | $ 1.19 | 0.01 % | $ 198 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
145 M | $ 1.45 | 2.13 % | $ 386 M | Britain |
 |
Aptose Biosciences
APTO
|
24.7 M | - | -45.71 % | $ 1.2 M | Canada |
 |
AstraZeneca PLC
AZN
|
17.6 B | - | - | $ 96.9 B | Britain |
 |
AVROBIO
AVRO
|
71.7 M | - | 1083.1 % | $ 745 M | USA |
 |
InflaRx N.V.
IFRX
|
52.4 M | $ 1.81 | 12.11 % | $ 152 M | Germany |
 |
Can-Fite BioPharma Ltd.
CANF
|
14 M | $ 2.98 | 2.05 % | $ 4.91 M | Israel |
 |
BeiGene, Ltd.
BGNE
|
390 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Inventiva S.A.
IVA
|
36.2 M | $ 5.14 | 0.19 % | $ 138 M | France |
 |
Akero Therapeutics
AKRO
|
80.2 M | - | - | $ 3.67 B | USA |
 |
bluebird bio
BLUE
|
854 M | - | - | $ 546 M | USA |